Antineoplastiske midler, og især alkylerende midler, har været forbundet med en mulig risiko for myelodysplastisk syndrom (MDS) og sekundære maligne lidelser, inklusive leukæmi.
Antineoplastic agents, and notably alkylating agents, have been associated with a potential risk of myelodysplastic syndrome (MDS) and secondary malignancies, including leukaemia.